These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 694)

  • 1. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115). 1. Blood levels in dogs].
    Femmer K; Klemm W; Nürnberger H
    Pharmazie; 1975 Oct; 30(10):673-5. PubMed ID: 694
    [No Abstract]   [Full Text] [Related]  

  • 2. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115) 2. Excretion, blood level and distribution of the 14C-labeled compound in the rat].
    Klemm W; Wenzel A
    Pharmazie; 1975 Oct; 30(10):675-7. PubMed ID: 695
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study on the chronic toxicity of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane(talinolol, Cordanum, 02-115) in the rat and the beagle].
    Bartsch R; Merbt EM; Riedel H
    Pharmazie; 1975 Oct; 30(10):659-68. PubMed ID: 691
    [No Abstract]   [Full Text] [Related]  

  • 4. [Quantitative colorimetric determination of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert butylaminopropane (talinolol Cordanum, 02-115) in body fluids].
    Nürnberger H
    Pharmazie; 1975 Oct; 30(10):673. PubMed ID: 693
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effects of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115), practolol and propranolol on the lipid content of the rat serum].
    Leonhardt U; Nürnberger H; Femmer K
    Pharmazie; 1975 Oct; 30(10):656-8. PubMed ID: 690
    [No Abstract]   [Full Text] [Related]  

  • 6. [The pharmacology of (+/-)-1-(4-cyclohexylureido-phenoxy)-2-hydroxy-3-tert-butylaminopropane (Talinolol, Cordanum, 02-115)].
    Femmer K; Bartsch R; Leonhardt U; von Littrow C; Riedel H
    Pharmazie; 1975 Oct; 30(10):642-51. PubMed ID: 688
    [No Abstract]   [Full Text] [Related]  

  • 7. Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker.
    Carruthers SG; Pentikainen P; Hosler JP; Azarnoff DL
    Clin Pharmacol Ther; 1979 Dec; 26(6):682-5. PubMed ID: 40725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
    Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
    Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood concentrations and pharmacodynamic effects of SL 75212, a new beta-adrenoceptor antagonist, after oral and intravenous administration [proceedings].
    Bianchetti G; Gomeni R; Kilborn JR; Morselli PL; Taylor EA; Warrington SJ
    Br J Clin Pharmacol; 1979 Oct; 8(4):403P-404P. PubMed ID: 41556
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of a new beta-adrenergic blocking agent, the 1, ter-butyl-amino-3-(1,2,3,4-tetrahydro-1,4-ethano-8-hydroxy-5-naphthoxy)-2-propanol (K 5407).
    Goldaniga G; Montesanti L; Pianezzola E; Valzelli G
    Eur J Drug Metab Pharmacokinet; 1980; 5(1):9-20. PubMed ID: 6104601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
    Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
    Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopharmacological studies on the bronchoconstrictive side effect of the beta-receptor blockader talinolol (Cordanum, 02-115) in patients with asthma or chronic obstructive lung diseases].
    Kandt D; Hackenberger F
    Pharmazie; 1975 Oct; 30(10):681-3. PubMed ID: 697
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
    Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
    Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
    Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
    Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.
    Trausch B; Oertel R; Richter K; Gramatté T
    Biopharm Drug Dispos; 1995 Jul; 16(5):403-14. PubMed ID: 8527689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical investigation of o-(2-hydroxy-3-(tert.-butylamino)-propoxy)-benzonitrile under glucose load by means of continuous recording].
    Regula H; Papner B
    Arzneimittelforschung; 1974 Sep; 24(9):1328-30. PubMed ID: 4154767
    [No Abstract]   [Full Text] [Related]  

  • 18. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
    Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of betaxolol in middle aged patients.
    Bianchetti G; Thiercelin JF; Thenot JP
    Eur J Clin Pharmacol; 1986; 31(2):231-3. PubMed ID: 2879735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
    Gramatté T; Oertel R; Terhaag B; Kirch W
    Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.